Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Apellis Pharmaceuticals, Inc. Director's Dealing 2020

Apr 27, 2020

31417_dirs_2020-04-27_05a3dc3e-56d1-4c90-a971-e10a23ad5bb7.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Apellis Pharmaceuticals, Inc. (APLS)
CIK: 0001492422
Period of Report: 2020-04-02

Reporting Person: Brown Victoria L. (Program Team Lead)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 3125 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Option (Right to Buy) $18.98 2029-03-06 Common Stock (70000) Direct
Stock Option (Right to Buy) $44.33 2030-02-09 Common Stock (12075) Direct
Stock Option (Right to Buy) $28.37 2030-03-24 Common Stock (6675) Direct

Footnotes

F1: Consist of shares of Common Stock issuable under 2,013 restricted stock units ("RSUs") granted on February 10, 2020 and 1,112 RSUs granted on March 25, 2020. Each RSU was granted pursuant to the Company's 2017 Stock Incentive Plan and represents the right to receive one share of Common Stock upon vesting. The RSUs will vest as to 25% of the shares underlying the RSUs on the first anniversary of the date of grant, and 25% of the shares underlying the RSUs on each anniversary of grant date thereafter through the fourth anniversary of the grant.

F2: This option was granted on March 7, 2019 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

F3: This option was granted on February 10, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.

F4: This option was granted on March 25, 2020 and will vest as to 25% of the shares underlying the options on the first anniversary of the grant, with the remaining 75% of the shares underlying the options vesting in equal monthly installments thereafter through the fourth anniversary of the grant, subject to continued service.